Insulet (NSDQ:PODD) shares sunk after hours today on fourth-quarter results that beat the consensus forecast for revenue but appeared to miss on earnings.
The Acton, Mass.–based insulin delivery device maker posted profits of $5 million, or 8¢ per share, on sales of $209.4 million for the three months ended Dec. 31, 2019, for a 49.5% bottom-line slide on sales growth of 27%.